Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Artiva Biotherapeutics Inc (ARTV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.13-2.13%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ARTV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
ATM stock offering remains suspended | A supporting condition in Artiva Biotherapeutics Inc's published investment case. The stated target is ATM offering suspended until new prospectus filed. | Intact | ATM offering resumes without clear need | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making company rather than an established durable compounder. Its current long-term thesis is in a watch state, with low overall confidence and recent financial performance well below its industry cohort.
The evidence describes ARTV as cheap versus peers, but that comparison comes with medium confidence and does not offset its losses. The snapshot does not specify what earnings or business outcome the market assumes, so the expectations gap is unclear; low fragility means no specific fragility warning was flagged.
Near term, two reported earnings beats offer a positive signal, but the broader financial performance remains weak and the next results carry elevated miss risk. Management has announced a workforce reduction of about 94% and halted AlloNK development after response durability fell short of its stated requirement, while savings from the reduction are not yet demonstrated. The company reported about $319.1 million in preliminary cash, cash equivalents, and investments as of September 30, 2026, but no outcome from its strategic alternatives process was reported.
The near-term setup depends partly on whether management cuts guidance on its next call and whether weaker employment data deepens recession concerns for cyclical companies. Over the multi-year view, the thesis also hinges on execution of the workforce reduction and strategic alternatives process, alongside continued support from healthcare-sector earnings momentum.
Over the next 1 to 3 years, ARTV remains a fragile, loss-making thesis with some cash resources and sector support, but limited evidence so far that management’s changes have improved the business. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Artiva Biotherapeutics Inc's published investment case. The stated target is No further significant insider stock sales. |
| Under Pressure |
| continued insider selling over next 12 months |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
FDA RMAT designation and clinical data milestones | FDA gave RMAT status. | Intact | clinical data not shared by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches about $108 million | A primary condition in Artiva Biotherapeutics Inc's published investment case. The stated target is about $108 million. | Intact | revenue falls below $50 million by mid-2027 | Revenue: $0 FY2026-Q2; GAAP. Published target: about $108 million. Target period ends 2027-06-30; this observation covers 2026-Q2. Aug 6, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.81 → $-1.93 · observed estimates
$0.00B → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.81 | $0 | 4 / 6 |
| 2026-07-25 | $-2.81 | $0 | 4 / 6 |
| 2026-07-26 | $-2.81 | $0 | 4 / 6 |
| 2026-07-27 | $-2.91 | Unavailable | 4 / 0 |
| 2026-07-28 | $-2.81 | $0 | 4 / 6 |
| 2026-07-29 | $-2.81 | $0 | 4 / 6 |
| 2026-07-30 | $-2.81 | $0 | 4 / 6 |
| 2026-07-31 | $-2.81 | $0 | 4 / 6 |
| 2026-08-01 | $-2.81 | $0 | 4 / 6 |
| 2026-08-02 | $-2.81 | $0 | 4 / 6 |
| 2026-08-03 | $-2.81 | $0 | 4 / 6 |
| 2026-08-04 | $-2.81 | $0 | 4 / 6 |
| 2026-08-05 | $-2.81 | $0 | 4 / 6 |
| 2026-08-06 | $-2.81 | $0 | 4 / 6 |
| 2026-08-07 | $-2.91 | Unavailable | 4 / 0 |
| 2026-08-08 | $-2.81 | $0 | 4 / 6 |
| 2026-08-09 | $-2.81 | $0 | 4 / 6 |
| 2026-08-10 | $-2.81 | $0 | 4 / 6 |
| 2026-08-11 | $-2.61 | $0 | 5 / 6 |
| 2026-08-12 | $-2.61 | $0 | 5 / 6 |
| 2026-08-13 | $-2.61 | $0 | 5 / 6 |
| 2026-08-14 | $-2.91 | Unavailable | 4 / 0 |
| 2026-08-15 | $-2.91 | Unavailable | 4 / 0 |
| 2026-08-16 | $-2.91 | Unavailable | 5 / 0 |
| 2026-08-17 | $-2.91 | Unavailable | 5 / 0 |
| 2026-08-18 | $-2.91 | Unavailable | 5 / 0 |
| 2026-08-19 | $-2.91 | Unavailable | 5 / 0 |
| 2026-08-20 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-21 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-22 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-23 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-24 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-25 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-26 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-27 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-28 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-29 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-30 | $-2.70 | Unavailable | 5 / 0 |
| 2026-08-31 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-01 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-02 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-03 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-04 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-05 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-06 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-07 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-08 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-09 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-10 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-11 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-12 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-13 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-14 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-15 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-16 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-17 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-18 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-19 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-20 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-21 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-22 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-23 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-24 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-25 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-26 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-27 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-28 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-29 | $-2.70 | Unavailable | 5 / 0 |
| 2026-09-30 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-01 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-02 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-03 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-04 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-05 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-06 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-07 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-08 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-09 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-10 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-11 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-12 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-13 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-14 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-15 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-16 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-17 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-18 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-19 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-20 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-21 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-22 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-23 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-24 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-25 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-26 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-27 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-28 | $-2.70 | Unavailable | 5 / 0 |
| 2026-10-29 | $-1.93 | Unavailable | 5 / 0 |
| 2026-10-30 | $-1.93 | Unavailable | 5 / 0 |
| 2026-10-31 | $-1.93 | Unavailable | 5 / 0 |
| 2026-11-01 | $-1.93 | Unavailable | 5 / 0 |
| 2026-11-02 | $-1.93 | Unavailable | 5 / 0 |
| 2026-11-03 | $-1.93 | Unavailable | 5 / 0 |
| 2026-11-04 | $-1.93 | Unavailable | 5 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.